Company intelligence / Profile preview

SIME Diagnostics

London, England, United Kingdom

Ownership: Private
Employees: ~29
Development stage: Other

Overview

SIME has received CE Mark for investigational use for its point-of-care device that predicts severe lung disease in ICU and NICU settings. The company published clinical study results demonstrating reduced pulmonary surfactant in COVID-19 ARDS patients and is preparing for commercial launch.

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: DeviceArtificial intelligence platform
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on SIME Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIME Diagnostics.

Explore the full profile